Insilico Medicine
AI-powered drug discovery
Exposure: $29.0M
Portfolio
Conviction calls.
We invest in companies at the forefront of scientific breakthroughs — precision medicine, AI-embedded drug discovery, biologics, and antimicrobial resistance solutions.
Darwin Health
Precision oncology
Exposure: $23.5M
Dragonfly Therapeutics
Immuno-oncology
Exposure: $15.0M
Tactogen
Neuropsychiatry
Exposure: $12.6M
Locus Biosciences
Precision antimicrobials
Exposure: $8.0M
F2G
Antifungal therapeutics
Exposure: $16.0M
Molecular Partners
DARPin therapeutics
Exposure: $9.0M
Position figures represent aggregate exposure across funds, co-investment vehicles and managed mandates, and may include primary, secondary and co-investment positions. Selected positions shown; complete portfolio disclosed under NDA to qualified institutional partners.